Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has set a new benchmark in its financial performance for the first quarter of 2024, demonstrating significant growth across all business segments. The company reported record quarterly net revenues of $137.4 million, marking a year-over-year increase of 28.7%. This growth was propelled by a notable performance in the Rare Disease business, which saw net revenues soar to $36.9 million, a staggering 126.2% increase from the previous year. Such robust growth underscores the increasing market penetration and expansion of the overall ACTH market, particularly for their lead Rare Disease asset, Cortrophin Gel.
The adjusted non-GAAP EBITDA reached a record $37.6 million, alongside an adjusted non-GAAP diluted EPS of $1.21. These figures not only reflect the company’s operational excellence and successful new product launches but also highlight the strategic investments made to expand awareness and utilization of Cortrophin Gel in new specialties. The company’s ability to maintain momentum in its Generics, Established Brands, and Other segment, achieving a double-digit increase in Generics revenue, further emphasizes its operational strength and market agility.
ANI Pharmaceuticals Surpasses Q1 Expectations with $1.21 EPS and $137.4 Million in Revenues
Comparing ANI’s current performance against expectations reveals a narrative of significant overachievement. Analysts had projected an EPS of $0.98 and revenue expectations of $125.35 million for the quarter. ANI’s reported EPS of $1.21 and revenues of $137.4 million comfortably surpassed these forecasts, indicating a robust financial health and operational efficiency exceeding market expectations. This outperformance is particularly noteworthy in the context of the Rare Disease segment, where Cortrophin Gel’s revenue of $36.9 million far exceeded expectations, driven by increased prescription demand across core and new specialties. The company’s Generics, Established Brands, and Other segment also outperformed, with revenue growth of 11.1% year-over-year, further contributing to the company’s overall success.
Join our Telegram group and never miss a breaking story.
ANI Reiterates Guidance for Full Year 2024, Expects Non GAAP EPS Between $4.26 to $4.67
Looking ahead, ANI has reiterated its guidance for the full year 2024, projecting net revenues in the range of $520 million to $542 million and adjusted non-GAAP EBITDA between $135 million and $145 million. The adjusted non-GAAP earnings per share are expected to be between $4.26 and $4.67. This guidance includes anticipated net revenues from Cortrophin Gel ranging from $170 million to $180 million, which would represent a year-over-year growth of 52% to 61%. Such projections reflect the company’s confidence in its strategic initiatives and the continued growth trajectory of its Rare Disease business. ANI’s commitment to enhancing its generics business, coupled with the strategic focus on its Rare Disease segment, positions the company well for sustainable growth and long-term value creation for its stakeholders.
Disclaimer: The author does not hold or have a position in any securities discussed in the article.
The post ANI Pharmaceuticals Beats Expectations with $137.4 Million in Q1 Revenues appeared first on Tokenist.